Lexicon Pharmaceuticals (NASDAQ: LXRX)
Lexicon Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Lexicon Pharmaceuticals Company Info
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
News & Analysis
Why Shares of Lexicon Pharmaceuticals Are Up Tuesday
Express Scripts will give its clients access to Lexicon's first approved therapy.
This Growth Stock Is Falling, But It Could Soon Fly High. Here's Why You Should Buy It
Lexicon Pharmaceuticals' fundraising activity is painful for shareholders right now, but it's critical.
Why Lexicon Pharmaceuticals Stock Crashed This Week
A capital raise weighed on the company's stock.
Wall Street's Counting on an FDA Nod for This Growth Stock to Nearly Double, but Should You?
Lexicon is approaching a fork in the road, and it needs permission to advance.
Should You Buy This Growth Stock Right Now Before It Doubles?
It could skyrocket or it could tank, but it probably won't be sitting still soon.
Why Lexicon Pharmaceuticals Was Plunging on Monday
The shares are reeling from disquieting news about the company's leading pipeline drug.
Should You Buy Lexicon Pharmaceuticals Stock?
Your portfolio could benefit from its group of soon-to-be-commercialized drugs.
3 Biotech Stocks That Jumped Last Week
Find out what led to the biotech industry's biggest gains.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.